CSL (OTCMKTS:CSLLY) Trading 23.5% Higher – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price shot up 23.5% on Wednesday . The company traded as high as $29.71 and last traded at $29.59. 38,875 shares were traded during trading, a decline of 91% from the average session volume of 411,140 shares. The stock had previously closed at $23.95.

Analysts Set New Price Targets

A number of brokerages have recently commented on CSLLY. Jefferies Financial Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. Five investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

CSL Stock Performance

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. The company’s fifty day moving average is $21.34 and its 200 day moving average is $27.26.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.